Lipocine's LPCN 1154 Phase 3 PPD trial misses primary endpoint; post hoc signals

Lipocine Inc.

Primary endpoint not met: no statistically significant HAM-D17 reduction vs placebo at hour 60 in full population (N=90).
Post hoc analysis of participants with psychiatric history (n=54) showed nominal significant reductions from hour 12 through day 30.
LPCN 1154 was well tolerated; no SAEs, excessive sedation, or treatment-related discontinuations reported.
Company evaluating all options, including further LPCN 1154 development, strategic transactions, and FDA designations (breakthrough/fast track applied).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.